medigraphic.com
ISSN 1561-2929 (Print)

2016, Number 2

<< Back Next >>

RCAN 2016; 26 (2)

On the behavior of atherosclerosis biomarkers in blood hypertension

García SN, León ÁJL

Language: Spanish
References: 85
Page: 252-274
PDF size: 470.51 Kb.


ABSTRACT

Rationale: Cardiovascular disease (CVD) is one of the first global causes of mortality. Development of atherosclerotic plaques progressively occluding arterial lumen lies at CVD onset. Blood hypertension (HBP) is one of the main risk factors for CVD onset. Novel atherosclerosis biomarkers have been described for detecting those subjects not necessarily identified by those traditionally ones used. Objective: To assess the behavior of novel atherosclerosis biomarkers in HBP not complicated with damage to target-organs. Study design: Analytical, cross-sectional. Study serie: One-hundred HBP patients (Males: 56.0%; Ages ≥ 60 years: 22.0%; HBP Stage I: 78.0%; Evolution ‹ 5 years: 49.0%) without damage to target-organs consecutively assisted at the Outpatient Clinic, Service of Internal Medicine, “Hermanos Ameijeiras” Hospital (Havana city, Cuba). Material and method: Associations between Carotid intima-media thickness (CIM), presence of albuminuria, and serum concentrations of glycated hemoglobin (HbA1c), troponin T (TnT), blood natruretic peptide (BNP), high sensitivity C reactive protein (hsCRP), fibrinogen and C Cystatin (Cyst) were examined. Results: An augmented GIM was associated with elevated serum Creatinine and reduced glomerular filtration rate. Albuminuria was prevalent among HBP subjects. Conclusions: Serum Creatinine can signal HBP patients with atherosclerosis of kidney vasculature.


REFERENCES

  1. Moran AE, Forouzanfar MH, Roth G, Mensah G, Ezzati M, Murray CJ, Naghavi M. Temporal trends in ischemic heart disease mortality in 21 world regions, 1980-2010: The Global Burden of Disease 2010 Study. Circulation 2014; 129:1483-92.

  2. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD; et al. Forecasting the future of cardiovascular disease in the United States. A policy statement from the American Heart Association. Circulation 2011;123:933-44.

  3. Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe 2014: Epidemiological update. Eur Heart J 2014;35:2929-33.

  4. Gaziano TA. Cardiovascular disease in the developing world and its cost effective management. Circulation 2005; 112:3547-53.

  5. Eckel RH, Jakicic JM, Ard JD, de Jesus JM, Houston Miller N, Hubbard VS; et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63:2960-84.

  6. Bauer UE, Briss PA, Goodman RA, Bowman BA. Prevention of chronic disease in the 21st century: Elimination of the leading preventable causes of premature death and disability in the USA. The Lancet 2014;384(9937):45-52.

  7. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M; et al; for the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2012;33:1635-701.

  8. Badimon J, Badimon L, Fuster V. Fisiopatología de la enfermedad aterosclerótica coronaria. Clin Invest Ateroscl 2002;14:258-71.

  9. Steg PG, Goldberg RJ, Gore JM; et al. Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). Am J Cardiol 2002;90:358-63.

  10. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J; et al. From vulnerable plaque to vulnerable patient: A call for new definitions and risk assessment strategies: Part I. Circulation 2003;108: 1664-72.

  11. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J; et al. From vulnerable plaque to vulnerable patient: A call for new definitions and risk assessment strategies: Part II. Circulation 2003;108: 1772-8.

  12. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97: 1837-47.

  13. Waxman S, Ishibashi F. Muller JE. Detection and treatment of vulnerable plaques and vulnerable patients: Novel approaches to prevention of coronary events. Circulation 2006;114:2390-411.

  14. Schaar JA, Muller JE, Falk E, Virmani R, Fuster V, Serruys PW; et al. Terminology for high-risk and vulnerable coronary artery plaques. Eur Heart J 2004;25:1077-82.

  15. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995;92: 657-71.

  16. Muller JE, Abela GS, Nesto RW, Tofler GH. Triggers, acute risk factors and vulnerable plaques: The lexicon of a new frontier. J Am Coll Cardiol 1994;23:809- 13.

  17. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: Analysis of worldwide data. Lancet 2005;365(9455): 217-23.

  18. Mittal BV, Singh AK. Hypertension in the developing world: Challenges and opportunities. Am J Kidney Dis 2010; 55:590-8.

  19. Bonet Gorbea M, Varona Pérez P. III Encuesta nacional de factores de riesgo y actividades preventivas de enfermedades no trasmisibles. Cuba 2010-2011. Editorial Ciencias Médicas. La Habana: 2014. Disponible en: http://www.bvs.sld.cu/libros/encuesta_na cional_riesgo/indice_p.htm. Fecha de última visita: 12 de Julio del 2016.

  20. Kannel WB, Schwartz MJ, McNamara PM. Blood pressure and risk of coronary heart disease: The Framingham Study. Dis Chest 1969;56;43-52.

  21. Kannel WB, Gordon T, Schwartz MJ. Systolic versus diastolic blood pressure and risk of coronary heart disease: The Framingham Study. Am J Cardiol 1971; 27:335-46.

  22. MacMahon S, Peto R, Collins R, Godwin J, Cutler J, Sorlie P; et al. Blood pressure, stroke, and coronary heart disease: Part 1, prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias. The Lancet 1990;335(8692):765-74.

  23. Collins R, Peto R, MacMahon S, Godwin J, Qizilbash N, Hebert P; et al. Blood pressure, stroke, and coronary heart disease: Part 2, short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. The Lancet 1990;335(8693):827-38.

  24. Wang JG, Staessen JA, Franklin SS, Fagard R, Gueyffier F. Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome. Hypertension 2005;45:907-13.

  25. Kannel WB. Blood pressure as a cardiovascular risk factor: Prevention and treatment. JAMA 1996;275:1571-6.

  26. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: A meta-analysis. The Lancet 2001;358(9290):1305-15.

  27. Schillaci G, Reboldi G, Verdecchia P. High-normal serum creatinine concentration is a predictor of cardiovascular risk in essential hypertension. Arch Intern Med 2001; 161:886-91.

  28. Wannamethee SG, Shaper AG, Perry I. J. Serum creatinine concentration and risk of cardiovascular disease: A possible marker for increased risk of stroke. Stroke 1997;28:557-63.

  29. Shurtleff D. The Framingham Study: An epidemiological investigation of cardiovascular disease [Editores: Kannel WB, Gordon T]. US Department of Health, Education, and Welfare. Public Health Service. National Institutes of Health. Bethesda: 1974.

  30. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels: The Framingham Study. JAMA 1986;256: 2835-8.

  31. Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ; et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003;290:898-904.

  32. Bugiardini R, Manfrini O, De Ferrari GM. Unanswered questions for management of acute coronary syndrome: Risk stratification of patients with minimal disease or normal findings on coronary angiography. Arch Intern Med 2006;166:1391-5.

  33. Pasternak RC, Abrams J, Greenland P, Smaha LA, Wilson PW, Houston Miller N; for the 34th Bethesda Conference Task Force #1. Identification of coronary heart disease risk: Is there a detection gap? J Am Coll Cardiol 2003;41: 1863-74.

  34. Gensini GF, Comeglio M, Colella A. Classical risk factors and emerging elements in the risk profile for coronary artery disease. Eur Heart J 1998; 19(Suppl):A53-A61.

  35. Greenland P, Smith Jr SC, Grundy SM. Improving coronary heart disease risk assessment in asymptomatic people: Role of traditional risk factors and noninvasive cardiovascular tests. Circulation 2001;104:1863-7.

  36. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein (a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001;285:2481-5.

  37. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on Atrial Fibrillation. Chest J 2010;137:263-72.

  38. Fernández-Britto Rodríguez JE. La lesión aterosclerótica: Estado del arte a las puertas del siglo XXI. Rev Cubana Invest Biomed 1998;17:112-27.

  39. Guterbaum T, Gæde P. Multiple risk factor intervention to prevent cardiovascular disease. A high powered and evidence based approach. Rev Esp Cardiol 2011;64:173-4.

  40. Bakris GL. New insights from risk factors to treatment implications. Nature Rev Cardiol 2012;9:75-7.

  41. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295:180-9.

  42. Zethelius B, Berglund L, Sundstrom J, Ingelsson E, Basu S, Larsson A; et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008;358:2107-16.

  43. Fernández Miranda C, para el Grupo Multidisciplinario para el estudio del Riesgo Cardiovascular. Nuevas perspectivas en la medición del riesgo cardiovascular: Exploraciones para detectar la aterosclerosis subclínica y marcadores de inflamación. Medicina Clínica [Barcelona] 2007;128:344-51.

  44. Carbayo Herencia JA. Nuevos marcadores de riesgo cardiovascular. Pueden influir en la clasificación del riesgo cardiovascular? Clin Invest Arterioscl 2012;24:57-70.

  45. Tartaglione J. ¿Son necesarios los biomarcadores para la detección de pacientes de riesgo? Rev Argentina Cardiología 2010;78:245-6.

  46. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M; et al; for the Task Force for the Management of Arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013 ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens 2013;31:1281-357.

  47. Martínez C, Pérez González R, Córdoba Vargas L, Santín Peña M, Macías Castro I. Programa nacional de prevención, diagnóstico, evaluación y control de la hipertensión arterial. Rev Cubana Med Gen Integr 1999;15:46-88.

  48. De Groot E, Hovingh GK, Wiegman A, Duriez P, Smit AJ, Fruchart JC; et al. Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. Circulation 2004;109:33-8.

  49. Salonen JT, Salonen R. Ultrasonographically assessed carotid morphology and the risk of coronary heart disease. Arterioscler Thromb 1991; 11:1245-9.

  50. Aminbakhsh A, Mancini GBJ. Carotid intima-media thickness measurements: What defines an abnormality? A systematic review. Clin Invest Med 1999;22:149-57.

  51. Weiner JS, Lourie JA. Human biology. A guide to field methods. International Biological Program. Handbook number 9. Blackwell Scientific Publications. Oxford: 1969.

  52. Lohman TG, Roche AF, Martorell R. Anthropometric standardization reference manual. Second Edition. Human Kinetics Books. Champaign [Illinois]: 1991. Pp 44-47.

  53. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. Disponible en: http://www.idf.org/webdata/docs/IDF_M eta_def_final.pdf. Fecha de última visita: 11 de Diciembre del 2015.

  54. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499- 502.

  55. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; for the Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 1999;130: 461-70.

  56. Grubb A, Bjork J, Lindstrom V, Sterner G, Bondesson P, Nyman U. A cystatin C-based formula without anthropometric variables estimates glomerular filtration rate better than creatinine clearance using the Cockcroft-Gault formula. Scand J Clin Lab Invest 2005;65:153-62.

  57. Grubb A, Nyman U, Bjork J, Lindstrom V, Rippe B, Sterner G; et al. Simple cystatin C-based prediction equations for glomerular filtration rate compared with the modification of diet in renal disease prediction equation for adults and the Schwartz and the Counahan-Barratt prediction equations for children. Clin Chem 2005;51:1420-31.

  58. Microalb-Látex. Juego de reactivos para la determinación de albúmina en muestras de orina. Manual del usuario. Registro número 0308-15. Helfa Diagnósticos. La Habana. Cuba.

  59. Santana Porbén S, Martínez Canalejo, H. Manual de Procedimientos Bioestadísticos. Editorial EAE Académica Española. Madrid: 2012.

  60. Santana Porbén S, Martínez Canalejo H. Manual de Estadísticas no Paramétricas. Editorial Publicia. Saarbrücken: 2013. ISBN: 978-3-639-55468-7.

  61. Samet JM, Soon-Young Y. Gender, women, and the tobacco epidemic. World Health Organization. Geneva: 2010. Disponible en: http://www.who.int/iris/handle/10665/44 342. Fecha de última vista: 20 de Mayo del 2015.

  62. Acosta Jiménez SM, Rodríguez Suárez A, Díaz Sánchez ME. La obesidad en Cuba. Una mirada a su evolución en diferentes grupos poblacionales. RCAN Rev Cubana Aliment Nutr 2013;23: 297-308.

  63. Inker LA, Okparavero A. Cystatin C as a marker of glomerular filtration rate: Prospects and limitations. Cur Op Nephrol Hypertension 2011;20:631-9.

  64. Pilote L, Dasgupta K, Guru V, Humphries KH, McGrath J, Norris C; et al. A comprehensive view of sex-specific issues related to cardiovascular disease. CMAJ 2007;176(Suppl):S1-S44.

  65. Helfand M, Buckley DI, Freeman M, Fu R, Kevin Rogers, Fleming C; et al. Emerging risk factors for coronary heart disease: A summary of systematic reviews conducted for the U.S. preventive services Ann Intern Med 2009;151:496-507.

  66. Badimón JJ, Santos-Gallego CG, Torres F, Castillo J, Kaski JC. Nuevas herramientas en la estratificación del riesgo cardiovascular. Rev Esp Cardiol 2011;11(Suppl):B21-B28.

  67. Jurkovitz CT, Abramson JL, Vaccarino LV, Weintraub WS, McClellan WM. Association of high serum creatinine and anemia increases the risk of coronary events: Results from the prospective community-based Atherosclerosis Risk In Communities (ARIC) Study. J Am Soc Nephrol 2003;14:2919-25.

  68. Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, Patsch W. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein (a), apolipoproteins AI and B, and HDL density subfractions in the Atherosclerosis Risk In Communities (ARIC) Study. Circulation 2001;104: 1108-13.

  69. Haskell WL, Alderman EL, Fair JM, Maron DJ, Mackey SF, Superko HR; et al. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). Circulation 1994;89:975-90.

  70. The Emerging Risk Factors Collaboration. C-Reactive Protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med 2012;367: 1310-20.

  71. Acevedo M, Arnáiza P, Barja S, Bambs C, Berríos X, Guzmán B; et al. Proteína C reactiva y su relación con adiposidad, factores de riesgo cardiovascular y aterosclerosis subclínica en niños sanos. Rev Esp Cardiol 2007;60:1051-8.

  72. Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, Sharrett AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: The Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol 1997;146:483-94.

  73. Hemmelgarn BR, Manns BJ, Lloyd A, James MT, Klarenbach S, Quinn RR; et al. Relation between kidney function, proteinuria, and adverse outcomes. JAMA 2010;303:423-9.

  74. Ix JH, Shlipak MG, Chertow GM, Whooley MA. Association of Cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: Data from the Heart and Soul Study. Circulation 2007;115:173-9.

  75. Rodilla E, Costa JA, Pérez Lahiguera F, González C, Miralles A, Pascual JM. Relación del cistatina C con otros parámetros de riesgo vascular en pacientes con hipertensión arterial. Medicina Clínica [Barcelona] 2008; 130:6-9.

  76. Hsu CC, Brancati F, Astor B, Kao WH, Steffes M, Folsom AR; et al. Blood pressure, atherosclerosis, and albuminuria in 10,113 participants of the Atherosclerosis Risk in Communities (ARIC) Study. Hypertension 2009;27: 397-409.

  77. Jensen JS, Feldt-Rasmussen B, Borch- Johnsen K, Clausen P, Appleyard M, Jensen G. Microalbuminuria and its relation to cardiovascular disease and risk factors. A population-based study of 1254 hypertensive individuals. J Hum Hypertens 1997;11:727-32.

  78. Newman DJ, Pugia MJ, Lott JA, Wallace JF, Hiar AM. Urinary protein and albumin excretion corrected by creatinine and specific gravity. Clin Chim Acta 2000; 294:139-55.

  79. Guy M, Borzomato JK, Newall RG, Kalra PA, Price CP. Protein and albumin-to-creatinine ratios in random urines accurately predict 24 h protein and albumin loss in patients with kidney disease. Ann ClinBiochem 2009;46: 468-76.

  80. Salabarría González JR, Santana Porbén S, Liriano Ricabal MR. Concentración urinaria de una sustancia a partir del índice de excreción. Rev Latinoam Patol Clin Med Lab 2015;62:119-26.

  81. Elosua R, Morales Salinas A. Determinación del riesgo cardiovascular total. Caracterización, modelización y objetivos de la prevención según el contexto sociogeográfico. Rev Esp Cardiol 2011;11(Supl):E2-E12.

  82. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R; et al. Guías de práctica clínica sobre prevención de la enfermedad cardiovascular: Versión resumida. Rev Esp Cardiol 2008;61(1):e1-e49.

  83. García Sánchez N, León Álvarez JL. Biomarcadores de la arteriosclerosis como predictores del riesgo cardiovascular en la hipertensión arterial no complicada. RCAN Rev Cubana Aliment Nutr 2016;26(2):275-283.

  84. Voutilainen S, Alfthan G, Nyyssönen K; et al. Association between elevated plasma total homocysteine and increased common carotid artery wall thickness. Ann Med 1998;30:300-6.

  85. Rosabal Nieves EL, Denis de Armas R, Leyva Quert AY. La homocisteína como indicador de la efectividad del intervencionismo coronario percutáneo. RCAN Rev Cubana Aliment Nutr 2015; 25:276-91.




2020     |     www.medigraphic.com